

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Guangzhou Innogen Pharmaceutical Group Co., Ltd.

廣州銀諾醫藥集團股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2591)

**VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE ON CLINICAL TRIAL OF CORE PRODUCT IN
AUSTRALIA**

This announcement is made by Guangzhou Innogen Pharmaceutical Group Co., Ltd. (the “**Company**”) to inform the shareholders of the Company (the “**Shareholders**”) and potential investors of its recent business updates.

As disclosed in the prospectus of the Company dated 7 August 2025, the Company planned to initiate a Phase II clinical trial of the Company's Core Product (i.e. Efsubaglutide Alfa) for the treatment of obesity and being overweight in Australia in the second half of 2025. The board (the “**Board**”) of directors of the Company (the “**Directors**”) is pleased to announce that on 25 August 2025, the Company has completed the first patient dosing in its Phase II clinical trial of the Core Product for the treatment of obesity and being overweight in Australia. The Company expects approximately 200 participants to be enrolled for such clinical trial.

Cautionary Statement: The Company cannot guarantee that it will be able to ultimately develop and/or market the Core Product successfully in Australia. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Dr. WANG QINGHUA
Chairman of the Board

Shanghai, the People's Republic of China, 26 August 2025

As at the date of this announcement, the Board comprises Dr. WANG QINGHUA, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing as executive Directors; Mr. HO KYUNG SHIK and Mr. Heng Lei as non-executive Directors; and Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony as independent non-executive Directors.